This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Ironwood Pharma (IRWD), Sionna Therapeutics, Inc. (SION)

Tipranks - Tipranks - Fri May 15, 3:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ironwood Pharma (IRWD) and Sionna Therapeutics, Inc. (SION) with bullish sentiments.

Claim 55% Off TipRanks

Ironwood Pharma (IRWD)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Ironwood Pharma yesterday. The company’s shares closed last Wednesday at $3.68.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 36.8% and a 58.4% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Fennec Pharmaceuticals, and Xtant Medical Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ironwood Pharma with a $7.50 average price target, implying an 85.4% upside from current levels. In a report issued on May 10, TipRanks – PerPlexity also upgraded the stock to Buy with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sionna Therapeutics, Inc. (SION)

Guggenheim analyst Yatin Suneja maintained a Buy rating on Sionna Therapeutics, Inc. yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $43.12.

According to TipRanks.com, Suneja is a 5-star analyst with an average return of 33.2% and a 58.0% success rate. Suneja covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sionna Therapeutics, Inc. with a $52.86 average price target, representing a 29.6% upside. In a report issued on May 5, Wedbush also initiated coverage with a Buy rating on the stock with a $53.00 price target.

Read More on IRWD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).